Clover Health Investments UBS Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Everyone, with us today we have Clover Health and Clay Thornton, the newly appointed CFO, moved from the interim role. Happy to have you here with us. I guess let's just start with you reported third quarter earnings. Let's provide a recap for everyone who may not be as familiar with Clover.
Yeah, absolutely. I view the third quarter really as a continuation of the momentum of the first two. On a year-to-date basis, we've now delivered $97 million of adjusted EBITDA, $62 million of net income. We're doing this while driving membership growth at roughly 50%. I think that's really important that we're finding a way this year to expand earnings while growing at a market-leading rate, and that really kind of just continued through the third quarter strong momentum, now setting us up for a really exciting 2027.
Yep. No, that's great. I guess let's start with talking about medical trend. Where is medical trend right now within your book of business, and is it easing relative to your expectations, and any areas to watch for from your perspective?
Relative to our expectations at the beginning of the year, we're certainly trending favorable to that. There's a couple areas that I would point to, one being inpatient, where utilization has been trending very favorable throughout the year across each of our cohorts, particularly our new member cohort that's trending at a utilization rate lower than last year's year one cohort. That's very encouraging for us. Second piece is on Part D. We've seen Part D trends come in lighter than we expected at the beginning of the year. That's largely been concentrated in the non-low-income population, which certainly had very high trends in 2025, the first year of the IRA impact on MA. Those trends have eased a little bit in '26 relative to our expectations at the beginning of the year.
On the flip side, though, with lower inpatient utilization can come higher utilization in the outpatient setting. We are seeing that in categories like outpatient surgery, observation visits, ER stays. That's playing out a little bit in the outpatient.
Okay, great. The company talked about significant growth for next year, 2027. I'm curious if you foresee this more as a gaining share from those exiting the market or more of that your general product is more competitive and you're taking share, and any way to frame the benefit that you're seeing this year from that dynamic?
It's definitely both. For the past two years, we've really prided ourselves on our product positioning and our competitive advantage there. That's continuing again into 2027. There are some new dynamics playing out in 2027, though. Most notably, there's a large plan exit in our core market of New Jersey. We have a plan exit that has membership in the range of about 40,000 MA members that'll be looking for a new home in 2027. That's a bit of a unique dynamic inside of this AEP, but our competitive positioning remains a significant strength, Jonathan. Every year, we kind of look at our benefits relative to the competition and try to size that difference. We're really at the same level, if not a little bit ahead in '27 relative to where we were in '20.
When you think about your pricing for '27, you previously said that you're not that much different from your large national peers. I'm curious if in that construct you also assumed a higher level of enrollment growth, or how did you kind of think about that within your trend assumptions?
Yeah. First, I want to clarify what we mean when we say pricing. Pricing meaning what trends were we assuming within our bids. When we are assuming trends in our bids, we are looking at normal unit cost, normal utilization metrics, and how we expect those to play out, but we are applying those trends across each cohort individually. With Clover, who has been growing incredibly fast over the past two years and expecting another strong year of growth in 2027, it is important to look at those cohorts kind of independent of each other and apply those trend assumptions uniformly to the different cohorts. When you aggregate all of that up, Jonathan, what often happens is our aggregated trend assumption might be a little lighter than some of the national peers because we are bringing in new members.
We have a higher membership weighting in that first, second, third year cohort than others do, and those cohorts generally run lower on a medical cost. In the aggregate, you will likely see a lower trend, but at the individual kind of factor level, we are generally making similar assumptions.
Okay, great. For switchers that come into your book, are they operating at better margins compared to a typical year one member, or does their utilization pattern look a bit hotter than the typical member?
When you think about new members, we always bucket in three different categories. Did they come to Clover from another Medicare Advantage plan? Did they age into Medicare, or did they come to us from Medicare fee-for-service? The members that are switching from another Medicare Advantage plan always run significantly better MLRs than the other two buckets. We always look at those separately. Coming out of the 2026 AEP, about 85% of our new members were in fact switchers from other Medicare Advantage plans. Heading into 2027, with the disruption that I mentioned with the plan exit, we would expect that percentage to be the same or possibly even actually a little bit higher in 2027 AEP.
We have really good data from the last several years to understand when we enroll new members from other plans, how do they perform within Clover in the first year, and then what happens in the second year? When a new member joins us, we are able to tell where they came from, who their previous plan was. As we are anticipating this growth in 2027, we are spending a lot of time focused on which plans are these members going to come from? What was our historical experience when those members joined our plan? What does that mean for '27 overall? We have got really good data there and feel good about where that is headed for 2027.
Okay, great. When you think about your overall book of business, where do you think you could broadly be doing better from a cost management standpoint on trend? Is there any specific areas to kind of call out?
Yeah, I would say there is two areas. The first relates to continuing to double down on Clover Assistant. Driving more coverage in Clover Assistant is going to drive more impact on the medical savings. We released a number of clinical white papers that show the impact of Clover Assistant on medical cost management, particularly in the lens of clinical impact. As we drive more coverage in Clover Assistant, we will expect to see more impact on the clinical side. The second piece, I would say, is around provider payment integrity and continuing to focus there to drive more efficiency and provider payment integrity operations.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
